Total 6 results found.
Tag: Cellular signaling and toxicity Ordering
Galvin Vredenburg, PhD

Position: PhD student

Room: P2.40Tel: +31 20 5987593Email:

Position: PhD student

Room: P2.40Tel: +31 20 59 87593Email:

Dr. Chris Vos

Position: Assistant Professor

Dr. ir. J.C. Vos studied Molecular Sciences at the Agricultural University of Wageningen. He received his PhD in 1993 at the University of Amsterdam for his work carried out at the European Molecular Biology Laboratory (EMBL) at Heidelberg, Germany, on vaccinia virus gene regulation. He spend two post-doctoral terms at the Dutch Cancer Institute in Amsterdam studying (i) DNA transposition in Caenorhabditis elegans (ii) the structure of the human Transporter Associated with Antigen Processing. In 2000, he moved to the section of Biochemistry and Molecular Biology (BMB) of the Vrije Universiteit focusing on the macromolecular interactions involved in the biogenesis of ribosomes in Saccharomyces cerevisiae. Since june 2006, he is member of the section of Molecular Toxicology, studying stress-response in yeast related to drug bioactivation by Cyt P450 biotransformation.

Room: KA 283aTel: +31 20 5987569Email:



Prof.dr. Nico Vermeulen

Position: Head of Division of Molecular Toxicology

Professor Vermeulen graduated in Chemistry in 1975 at the Catholic University of Nijmegen. In 1980 he obtained his PhD in Pharmacology from the University of Leiden. In 1985 he was appointed professor of Molecular Toxicology at the Vrije Universiteit, Amsterdam.

Amongst others he is organizer of the yearly (Dutch) Post-academic Course on General Toxicology, the yearly international LACDR/EUFEPS course on High-Throughput Drug Metabolism and Disposition and of the PharmSciFair 2005 in Nice, a member of the Committee for the Registration of Toxicologists, chairman of the Section Pharmacochemistry of the Royal Netherlands Chemical Society (KNCV), a member of the Future Strategies Committee of the KNCV and councillor of the European Society of Biochemical Pharmacology (ESBP). In 2012 he chaired the first Joint MDO/European ISSX Meeting in Noordwijk, The Netherlands.

He was/is President-elect (2000-2001), President (2002-2003), Past-president (2004-2005) and Honorary Life-time member of the International Society for the Study of Xenobiotics (ISSX). In 2006, he received the European ISSX Scientific Achievement Award, and in 2011 an Honorary Doctorate from the University of Copenhagen.

Professor Vermeulen is on the editorial boards of the journals Biomarkers, Biomedical & Environmental Sciences, Biochemical Pharmacology, Chemico-Biological Interactions, Chirality, Chemistry & Biodiversity, Chemical Research in Toxicology, Drug Metabolism Reviews, Expert Opinions in Drug Metabolism & Toxicology, Toxicology and Xenobiotica. He is associate editor of Current Drug Metabolism/Drug Metabolism Letters and editor of Environmental Toxicology & Pharmacology.

Work of him and his group is since 2001 taken up in the ISI-list of Highly Cited Researchers.


Room: P2.22Tel: +31 20 5987590Email:

CV [pdf]

Cellular signaling and toxicity

People involved: Staff: J. Chris Vos, Nico P. E. VermeulenPhD Students: Galvin Vredenburg, Angelina HuseinovicShalenie Sewradj, Stefan Dekker, Katarzyna Lazarska


Research activities: The yeast Saccharomyces cerevisiae has been developed as an alternative eukaryotic model organism to study toxicity in response to drug exposure. To incorporate bioactivation, we expressed bacterial cytochroom P450 BM3 in yeast, notably a mutant with a high activity towards a variety of drugs. To correlate intracellular generation of metabolites with toxicity, yeast strains with and without expressed P450 BM3 are tested. Furthermore, we have introduced human glutathione-S-transferase and sulfotransferases in yeast to investigate phase II detoxification reactions.

Prof. dr. Nico Vermeulen from the Division of Molecular Toxicology and his staff members Dr. Jan Commandeur and Dr. Chris Vos have obtained a large grant for an Innovative Medicine Initiative project. With this funding, they aim to develop new test systems for drugs causing drug-induced liver injury in humans.

The Innovative Medicine Initiative project is entitled 'Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury'. It will address the improvement of existing and the development of novel in vivo and in vitro test systems for the prediction of drug-induced liver injury in humans. Drug-induced liver injury is main leading cause of liver failure and transplantation in western countries.

The total budget of the Innovative Medicine Initiative project is 34M EUR. Of this amount, 1.5M EUR is covering a 5-year contribution to the Division of Molecular Toxicology. With this grant, the division can hire 3 PhD students and a post-doc researcher and support them with significant additional funds for bench fees and equipment. This research project is the third Innovative Medicine Initiative project of group of Nico Vermeulen. In 2010, the IMI-SafeSciMET and IMI-eTOX projects were started.

Non-clinical test cascade

The consortium working on 'Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury' comprises key opinion leaders from universities, the biotechnology sector and the pharmaceutical industry. They share a common goal of improving the limited predictability or current drug-induced liver injury test systems.

The ultimate purpose is to develop a novel, non-clinical test cascade for this disease. This test cascade will be mechanism-based and/or of physiological, pharmacological and pathological relevance to drug-induced liver injury. The goal is to utilize the test cascade within the pharmaceutical industry to enable selection of drug candidates that have reduced propensity to cause drug-induced liver injury in humans.

Click here for more details on this project.